| Deepna Deepak Jaiswal, DO | |
|
1600 Coit Rd Ste 408, Plano, TX 75075-6173 | |
| (817) 759-7000 | |
| (817) 759-7027 |
| Full Name | Deepna Deepak Jaiswal |
|---|---|
| Gender | Female |
| Speciality | Hematology/oncology |
| Experience | 13 Years |
| Location | 1600 Coit Rd Ste 408, Plano, Texas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1447541594 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | R1782 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Medical City Plano | Plano, TX | Hospital |
| Medical City Las Colinas | Irving, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Oncology-hematology Consultants Pa | 5496646382 | 56 |
News Archive
Neuropeptide Y (NPY) is the most abundant peptide hormone of the central nervous system. It is involved in various processes including stress management, the development of anxiety behaviour and body weight regulation. A collaborative research group including scientists from the Max Planck Institute for Medical Research in Heidelberg has demonstrated using mice that intensive maternal care during infancy promotes the effect of NPY in the brain.
New research has revealed how three important brain signaling chemicals affect the way that we handle uncertainty.
Debiopharm Group, the Swiss-based global biopharmaceutical company that focuses on the development of prescription drugs that target unmet medical needs including oncology, today announced the start of a phase I, open label multicenter study of a selective FGFR 1, 2, 3 inhibitor, Debio 1347 (CH5183284) in patients with advanced solid tumors.
Universally screening pediatric patients for COVID-19 before they undergo surgical procedures has allowed hospitals to improve safety by identifying all patients who test positive for the virus, half of whom have no symptoms, according to new research led by Children's Hospital of Philadelphia
As part of its "Blueprint" series discussing the creation of a U.S. global AIDS blueprint called for by Secretary of State Hillary Clinton in July, the Center for Global Health Policy's "Science Speaks" blog features an interview with Rochelle Walensky, a member of Cost-Effectiveness of Preventing AIDS Complications (CEPAC) and the Office of AIDS Research Advisory Council at the NIH/DHS Panel on Antiretroviral Guidelines for Adults and Adolescents.
› Verified 2 days ago
| Entity Name | Oncology-hematology Consultants Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629021159 PECOS PAC ID: 5496646382 Enrollment ID: O20040322000664 |
News Archive
Neuropeptide Y (NPY) is the most abundant peptide hormone of the central nervous system. It is involved in various processes including stress management, the development of anxiety behaviour and body weight regulation. A collaborative research group including scientists from the Max Planck Institute for Medical Research in Heidelberg has demonstrated using mice that intensive maternal care during infancy promotes the effect of NPY in the brain.
New research has revealed how three important brain signaling chemicals affect the way that we handle uncertainty.
Debiopharm Group, the Swiss-based global biopharmaceutical company that focuses on the development of prescription drugs that target unmet medical needs including oncology, today announced the start of a phase I, open label multicenter study of a selective FGFR 1, 2, 3 inhibitor, Debio 1347 (CH5183284) in patients with advanced solid tumors.
Universally screening pediatric patients for COVID-19 before they undergo surgical procedures has allowed hospitals to improve safety by identifying all patients who test positive for the virus, half of whom have no symptoms, according to new research led by Children's Hospital of Philadelphia
As part of its "Blueprint" series discussing the creation of a U.S. global AIDS blueprint called for by Secretary of State Hillary Clinton in July, the Center for Global Health Policy's "Science Speaks" blog features an interview with Rochelle Walensky, a member of Cost-Effectiveness of Preventing AIDS Complications (CEPAC) and the Office of AIDS Research Advisory Council at the NIH/DHS Panel on Antiretroviral Guidelines for Adults and Adolescents.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Deepna Deepak Jaiswal, DO 800 W Magnolia Ave, Fort Worth, TX 76104-4611 Ph: (817) 759-7000 | Deepna Deepak Jaiswal, DO 1600 Coit Rd Ste 408, Plano, TX 75075-6173 Ph: (817) 759-7000 |
News Archive
Neuropeptide Y (NPY) is the most abundant peptide hormone of the central nervous system. It is involved in various processes including stress management, the development of anxiety behaviour and body weight regulation. A collaborative research group including scientists from the Max Planck Institute for Medical Research in Heidelberg has demonstrated using mice that intensive maternal care during infancy promotes the effect of NPY in the brain.
New research has revealed how three important brain signaling chemicals affect the way that we handle uncertainty.
Debiopharm Group, the Swiss-based global biopharmaceutical company that focuses on the development of prescription drugs that target unmet medical needs including oncology, today announced the start of a phase I, open label multicenter study of a selective FGFR 1, 2, 3 inhibitor, Debio 1347 (CH5183284) in patients with advanced solid tumors.
Universally screening pediatric patients for COVID-19 before they undergo surgical procedures has allowed hospitals to improve safety by identifying all patients who test positive for the virus, half of whom have no symptoms, according to new research led by Children's Hospital of Philadelphia
As part of its "Blueprint" series discussing the creation of a U.S. global AIDS blueprint called for by Secretary of State Hillary Clinton in July, the Center for Global Health Policy's "Science Speaks" blog features an interview with Rochelle Walensky, a member of Cost-Effectiveness of Preventing AIDS Complications (CEPAC) and the Office of AIDS Research Advisory Council at the NIH/DHS Panel on Antiretroviral Guidelines for Adults and Adolescents.
› Verified 2 days ago
Yinghui Liu, MD, PHD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 4020 Hedgcoxe Rd, Ste 700, Plano, TX 75024 Phone: 972-618-7800 Fax: 972-618-7900 | |
Dr. Mukesh Kumar D Delvadiya, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 6300 W. Parker Road, Suite 123, Mob Ii, Plano, TX 75093 Phone: 972-398-2899 Fax: 972-398-2837 | |
Dr. Ashesh Bakulesh Parikh, D.O. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 6300 W Parker Rd Ste 322, Plano, TX 75093 Phone: 972-981-7870 Fax: 972-981-7886 | |
Sean Allan Townsend, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 4716 Alliance Blvd, Suite 500, Plano, TX 75093 Phone: 469-800-6000 Fax: 469-800-6052 | |
Dr. Vijay Sitharam Ramanath, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 6124 W Parker Rd, Suite 536, Plano, TX 75093 Phone: 972-378-9560 Fax: 844-290-4363 | |
Samuel Afenir Piga, M.D. Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 3105 W 15th St, Suite E, Plano, TX 75075 Phone: 469-467-9755 Fax: 972-801-9917 | |
Dr. Maria Love Lee, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 6200 W Parker Rd, Plano, TX 75093 Phone: 972-293-5151 Fax: 972-981-3967 |